Cubist Systematic Strategies LLC Buys 147,843 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Cubist Systematic Strategies LLC boosted its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 724.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 168,252 shares of the biotechnology company's stock after purchasing an additional 147,843 shares during the period. Cubist Systematic Strategies LLC owned about 0.12% of Aurinia Pharmaceuticals worth $1,511,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership bought a new position in Aurinia Pharmaceuticals in the fourth quarter worth approximately $9,662,000. JPMorgan Chase & Co. raised its position in Aurinia Pharmaceuticals by 84.4% in the fourth quarter. JPMorgan Chase & Co. now owns 927,298 shares of the biotechnology company's stock worth $8,327,000 after acquiring an additional 424,482 shares during the period. Renaissance Technologies LLC raised its position in Aurinia Pharmaceuticals by 44.0% in the fourth quarter. Renaissance Technologies LLC now owns 700,900 shares of the biotechnology company's stock worth $6,294,000 after acquiring an additional 214,200 shares during the period. Vanguard Group Inc. raised its position in Aurinia Pharmaceuticals by 6.9% in the fourth quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company's stock worth $15,535,000 after acquiring an additional 112,113 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in Aurinia Pharmaceuticals by 22.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 556,454 shares of the biotechnology company's stock worth $4,997,000 after acquiring an additional 102,195 shares during the period. Institutional investors own 36.83% of the company's stock.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.

Aurinia Pharmaceuticals Price Performance

AUPH stock opened at $8.12 on Tuesday. Aurinia Pharmaceuticals Inc. has a 12 month low of $4.99 and a 12 month high of $10.67. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The company has a 50-day moving average price of $8.03 and a 200 day moving average price of $8.23. The stock has a market cap of $1.11 billion, a PE ratio of -54.13 and a beta of 1.16.

Insider Activity at Aurinia Pharmaceuticals

In other news, COO Matthew Maxwell Donley sold 65,902 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $527,216.00. Following the completion of the sale, the chief operating officer now owns 739,456 shares in the company, valued at approximately $5,915,648. The trade was a 8.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Greg Keenan sold 8,305 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $8.23, for a total transaction of $68,350.15. Following the completion of the transaction, the insider now directly owns 153,484 shares in the company, valued at approximately $1,263,173.32. The trade was a 5.13% decrease in their position. The disclosure for this sale can be found here. Insiders sold 343,898 shares of company stock worth $2,753,094 in the last 90 days. 4.30% of the stock is owned by corporate insiders.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.